Advanced Bioaerosols Technology Core

Information

  • Research Project
  • 10260848
  • ApplicationId
    10260848
  • Core Project Number
    U19AI162130
  • Full Project Number
    1U19AI162130-01
  • Serial Number
    162130
  • FOA Number
    RFA-AI-20-008
  • Sub Project Id
    9474
  • Project Start Date
    9/1/2021 - 2 years ago
  • Project End Date
    5/31/2026 - 2 years from now
  • Program Officer Name
  • Budget Start Date
    7/1/2021 - 2 years ago
  • Budget End Date
    6/30/2022 - a year ago
  • Fiscal Year
    2021
  • Support Year
    01
  • Suffix
  • Award Notice Date
    8/19/2021 - 2 years ago

Advanced Bioaerosols Technology Core

Project Summary/Abstract ? Advanced Bioaerosol Technology Core The Advanced Bioaerosol Technology Core (ABTC) will develop a comprehensive suite of innovative technologies for improved sampling, fractionation, culture, and characterization of influenza virus aerosols to enable new analytical capabilities in support of the U19 research project goals. The advanced technologies developed through the ABTC will be employed within each individual research project to yield more effective studies of airborne transmission and infectivity through a combination of efficient ambient sampling to evaluate size-dependent distributions of infective virus within the clinical environment, and high-resolution individual exhaled breath sampling to elucidate the fundamental source terms needed for accurate transmission modeling. The ABTC team will leverage expertise across the fields of bioengineering, bioaerosol system engineering, and respiratory virology to develop 5 interconnected technologies for advanced bioaerosol analysis. In Aim 1, a set of compact instruments will be developed for the collection and parallel size-based fractionation of ambient environmental aerosols to enable distributed monitoring of airborne virus during the proposed clinical studies. In Aim 2, a second aerosol sampling instrument employing a unique exhaled breath sampling technology will be developed to provide high resolution aerosol fractionation and collection, allowing us to evaluate both viable and non-infective virus emission from individual donors across narrow particle size ranges. To enhance infectivity characterization for sampled virus particles, a synthetic mucus hydrogel will be advanced in Aim 3 as a novel sample target for the environmental sampler, providing improved virus capture and cell culture, greatly improving virus capture and viability for downstream infectivity assays. A digital cell culture array technology will be developed in Aim 4, enabling the direct isolation of individual aerosol particles captured by the exhaled breath sampler, and allowing us to evaluate distribution and clustering of both viable and non-infective virus units at single particle resolution. The ABTC team will also develop an optimized cell line that will be employed for the analysis of virus collected with the developed instruments to enhance evaluation of infectivity. The core will validate the developed technologies for aerosol sampling, capture, isolation, culture, and analysis through a set of ferret studies before integration with the proposed U19 research projects, and will execute the required assays using clinical samples to support the goals of RP1 and RP2. The results of the ABTC research efforts will yield the instruments and technologies needed to enhance our understanding of influenza aerobiology, from the determination of critical source terms to the evaluation of infective particle distributions within the environment, supporting significant improvements to influenza transmission modeling, risk analysis, and mitigation, while making important contributions toward advancing our understanding of other respiratory viral pandemic threats.

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    U19
  • Administering IC
    AI
  • Application Type
    1
  • Direct Cost Amount
    913896
  • Indirect Cost Amount
    168158
  • Total Cost
  • Sub Project Total Cost
    1082054
  • ARRA Funded
    False
  • CFDA Code
  • Ed Inst. Type
  • Funding ICs
    NIAID:1082054\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
    ZAI1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    UNIV OF MARYLAND, COLLEGE PARK
  • Organization Department
  • Organization DUNS
    790934285
  • Organization City
    COLLEGE PARK
  • Organization State
    MD
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    207425141
  • Organization District
    UNITED STATES